25 June 2018
The excessive production of harmful autoantibodies is a hallmark of autoimmune disease. Recent research has also shown that autoantibody production is useful to characterize cancer patients. The characterization of patient sub groups is essential for the efficient development of therapies for both autoimmune disease and cancer. In this presentation, Hans-Dieter Zucht, Head of Technology, Protagen AG, describes the use of a Luminex-based assay to detect common reactivity patterns of human autoantibodies against endogenous protein targets, using clustered autoantibody reactivities.